BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169-1175. [PMID: 22544263 DOI: 10.1007/s10067-012-1988-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao P, Gao Q, He Q, Tan J. Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia. Int J Hematol 2017;106:484-9. [PMID: 28612279 DOI: 10.1007/s12185-017-2276-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, Ballanti E, Migliore A. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol. 2013;2013:410521. [PMID: 23606869 DOI: 10.1155/2013/410521] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
3 Felis-Giemza A, Olesińska M, Świerkocka K, Więsik-Szewczyk E, Haładyj E. Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatol Int 2015;35:385-92. [PMID: 25549599 DOI: 10.1007/s00296-014-3195-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
4 Chiu YM, Lai MS, Chan KA. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections. PLoS One 2018;13:e0196210. [PMID: 29694398 DOI: 10.1371/journal.pone.0196210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, Piette AM, Dernis E, Ebbo M, Fautrel B. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken). 2013;65:1504-1514. [PMID: 23436730 DOI: 10.1002/acr.21990] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
6 Zhang L, Yang S, Yu Y, Wang S, Yu Y, Jin Y, Zhao A, Mao Y, Lu L. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus. Hepatol Commun 2022. [PMID: 35593183 DOI: 10.1002/hep4.1994] [Reference Citation Analysis]
7 Cheung MC, Agarwal K. Liver abnormalities in the immunosuppressed. Best Practice & Research Clinical Gastroenterology 2013;27:597-618. [DOI: 10.1016/j.bpg.2013.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am 2017;43:133-49. [PMID: 27890170 DOI: 10.1016/j.rdc.2016.09.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
9 Lin WT, Chen YM, Chen DY, Lan JL, Chang CS, Yeh HZ, Yang SS. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus 2018;27:66-75. [PMID: 28534427 DOI: 10.1177/0961203317711009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
10 Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43 [DOI: 10.5315/wjh.v3.i2.29] [Reference Citation Analysis]
11 Kato M, Atsumi T. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. Rheumatol Int 2016;36:635-41. [PMID: 26573663 DOI: 10.1007/s00296-015-3395-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3. [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038] [Cited by in Crossref: 274] [Cited by in F6Publishing: 249] [Article Influence: 34.3] [Reference Citation Analysis]
13 Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis. Microb Pathog 2018;114:436-43. [PMID: 29223453 DOI: 10.1016/j.micpath.2017.12.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
14 Yu HC, Tseng JC, Lu LY, Hu JC, Chen YH, Hsu CL, Wu PC, Mar GY, Lin KH. Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy. Eur J Gastroenterol Hepatol 2021;33:107-13. [PMID: 32243344 DOI: 10.1097/MEG.0000000000001707] [Reference Citation Analysis]
15 Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2014;Epub ahead of print. [PMID: 24698305 DOI: 10.1111/1756-185x.12359] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
16 Eun Y, Kim IY, Jeong H, Kim H, Lee J, Choi MS, Koh E, Cha HS. Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. J Korean Med Sci 2018;33:e168. [PMID: 29853822 DOI: 10.3346/jkms.2018.33.e168] [Reference Citation Analysis]
17 Mallet V, van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P; ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016;16:606-17. [PMID: 27599653 DOI: 10.1016/S1473-3099(16)00118-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
18 Mo YQ, Liang AQ, Ma JD, Chen LF, Zheng DH, Schumacher HR, Dai L. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskelet Disord. 2014;15:449. [PMID: 25532827 DOI: 10.1186/1471-2474-15-449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
19 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
20 Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018;70:724-731. [PMID: 28834412 DOI: 10.1002/acr.23346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PMID: 29968197 DOI: 10.1007/s40261-018-0671-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
22 Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis. 2013;16:527-531. [PMID: 24164839 DOI: 10.1111/1756-185x.12154] [Cited by in Crossref: 67] [Cited by in F6Publishing: 30] [Article Influence: 8.4] [Reference Citation Analysis]
23 Long LH, Zeng ZL, Niu CY, Shi JF, Mao JJ, Yan J. Drug utilization review and drug utilization evaluation for evaluation of usage of hepatoprotective drugs in patients with hepatitis: Analysis of 129 cases. Shijie Huaren Xiaohua Zazhi 2014; 22(27): 4140-4145 [DOI: 10.11569/wcjd.v22.i27.4140] [Reference Citation Analysis]
24 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
25 Louthrenoo W. Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. Best Practice & Research Clinical Rheumatology 2015;29:319-42. [DOI: 10.1016/j.berh.2015.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
26 Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-490. [PMID: 29991894 DOI: 10.20524/aog.2018.0266] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
27 Zhong Z, Liao W, Dai L, Feng X, Su G, Gao Y, Wu Q, Yang P. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis 2021:annrheumdis-2021-221650. [PMID: 34933869 DOI: 10.1136/annrheumdis-2021-221650] [Reference Citation Analysis]
28 Lin TC, Hashemi N, Kim SC, Yang YK, Yoshida K, Tedeschi S, Desai R, Solomon DH. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken) 2018;70:30-8. [PMID: 28320050 DOI: 10.1002/acr.23241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
29 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. Clin Liver Dis 2019;23:521-34. [PMID: 31266625 DOI: 10.1016/j.cld.2019.04.012] [Reference Citation Analysis]
30 Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33:119-123. [PMID: 24077913 DOI: 10.1007/s10067-013-2385-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
31 Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48. [PMID: 34427860 DOI: 10.1007/s12072-021-10239-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
32 Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-puttini P, Galli M. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine 2017;84:525-30. [DOI: 10.1016/j.jbspin.2017.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
33 Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. Ann Pharmacother 2019;53:294-310. [PMID: 30203666 DOI: 10.1177/1060028018800501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
35 Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 2018;32:767-80. [PMID: 31427054 DOI: 10.1016/j.berh.2019.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
36 Friedman MA, Winthrop KL. Vaccines and Disease-Modifying Antirheumatic Drugs. Rheumatic Disease Clinics of North America 2017;43:1-13. [DOI: 10.1016/j.rdc.2016.09.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
37 Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33:577-586. [PMID: 24343455 DOI: 10.1007/s10067-013-2450-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
38 Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, Yesudian PD. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 2016;175:23-44. [PMID: 27484275 DOI: 10.1111/bjd.14816] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 8.6] [Reference Citation Analysis]
39 Peccerillo F, Odorici G, Pellacani G, Conti A. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. Dermatol Ther. 2018;31:e12601. [PMID: 29633448 DOI: 10.1111/dth.12601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
40 Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015; 21(36): 10274-10289 [PMID: 26420955 DOI: 10.3748/wjg.v21.i36.10274] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
41 Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, Winthrop KL, Baddley JW. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Res Ther 2015;17:136. [PMID: 26001631 DOI: 10.1186/s13075-015-0628-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
42 Jeong W, Choe J, Song B, Lee C, Cha H, Ghang B, Kim J. Effect of Low-Dose Corticosteroid Use on HBV Reactivation in HBsAg-positive Rheumatoid Arthritis Patients. TORJ 2021;15:39-44. [DOI: 10.2174/1874312902115010039] [Reference Citation Analysis]
43 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
44 Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep. 2013;15:319. [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
45 Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol 2016;28:330-6. [PMID: 26986246 DOI: 10.1097/BOR.0000000000000281] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases 2022; 10(1): 12-22 [DOI: 10.12998/wjcc.v10.i1.12] [Reference Citation Analysis]
47 Shahram F, Ghorbani S, Mahmoudi M, Akhlaghi M, Jadali Z, Imeni V, Norouzi M, Faezi ST, Monavari SHR, Mostafaei S, Poortahmasebi V, Barfi S, Alavian SM, Jazayeri SM. Characterization of Occult Hepatitis B Virus Infection Among Iranian Patients with Behcet's Disease; Correlation with Clinical Status. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.105078] [Reference Citation Analysis]
48 Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis 2017;76:1051-6. [PMID: 27934678 DOI: 10.1136/annrheumdis-2016-209973] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
49 Tung CH, Lai NS, Lu MC, Lee CC. Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan. Rheumatol Int 2016;36:199-205. [PMID: 26408009 DOI: 10.1007/s00296-015-3369-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]